Related references
Note: Only part of the references are listed.Effects of bromocriptine on Parkinsonism A nation-wide collaborative double-blind study
Yasuo Toyokura et al.
ACTA NEUROLOGICA SCANDINAVICA (2010)
Treatment options in the modern management of Parkinson Disease
Anthony H. V. Schapira
ARCHIVES OF NEUROLOGY (2007)
Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial
Werner H. Poewe et al.
LANCET NEUROLOGY (2007)
Transdermal rotigotine - Double-blind, placebo-controlled trial in Parkinson disease
Joseph Jankovic et al.
ARCHIVES OF NEUROLOGY (2007)
Valvular heart disease and the use of dopamine agonists for Parkinson's disease
Renzo Zanettini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease
Matthias R. Lemke et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2006)
Dopamine agonists and cardiac valvulopathy in Parkinson disease - A case-control study
Mitsutoshi Yamamoto et al.
NEUROLOGY (2006)
Novel pharmacological targets for the treatment of Parkinson's disease
Anthony H. V. Schapira et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Valvular heart disease in Parkinson's disease vs. controls:: An echocardiographic study
Cecilia Peralta et al.
MOVEMENT DISORDERS (2006)
Pramipexole versus sertraline in the treatment of depression in Parkinson's disease - A national multicenter parallel-group randomized study
Paolo Barone et al.
JOURNAL OF NEUROLOGY (2006)
Practice parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology
R Pahwa et al.
NEUROLOGY (2006)
Timing of treatment initiation in Parkinson's disease: A need for reappraisal?
AHV Schapira et al.
ANNALS OF NEUROLOGY (2006)
Pergolide versus levodopa monotherapy in early Parkinson's disease patients:: The PELMOPET study
WH Oertel et al.
MOVEMENT DISORDERS (2006)
Pramipexole protects against MPTP toxicity in non-human primates
MM Iravani et al.
JOURNAL OF NEUROCHEMISTRY (2006)
Non-motor symptoms of Parkinson's disease: diagnosis and management
KR Chaudhuri et al.
LANCET NEUROLOGY (2006)
SPG3A is the most frequent cause of hereditary spastic paraplegia with onset before age 10 years
M Namekawa et al.
NEUROLOGY (2006)
Evidence-based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004
CG Goetz et al.
MOVEMENT DISORDERS (2005)
Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity
R Hilker et al.
ARCHIVES OF NEUROLOGY (2005)
Neuroprotection in Parkinson disease - Mysteries, myths, and misconceptions
AHV Schapira et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms
M Gu et al.
JOURNAL OF NEUROCHEMISTRY (2004)
Disease modification in Parkinson's disease
A Schapira
LANCET NEUROLOGY (2004)
Excessive daytime sleepiness in Parkinson's disease
AH Schapira
NEUROLOGY (2004)
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study
AL Whone et al.
ANNALS OF NEUROLOGY (2003)
Neuroprotective agents for clinical trials in Parkinson's disease - A systematic assessment
BM Ravina et al.
NEUROLOGY (2003)
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes
MJ Millan et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Effects of coenzyme Q10 in early Parkinson disease -: Evidence of slowing of the functional decline
CW Shults et al.
ARCHIVES OF NEUROLOGY (2002)
The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service
AJ Hughes et al.
BRAIN (2002)
Pharmacology of dopamine agonists in the treatment of Parkinson's disease
P Jenner
NEUROLOGY (2002)
The dopamine agonist pramipexole scavenges hydroxyl free radicals induced by striatal application of 6-hydroxydopamine in rats: an in vivo microdialysis study
B Ferger et al.
BRAIN RESEARCH (2000)
Continuous dopamine-receptor stimulation in early Parkinson's disease
CW Olanow et al.
TRENDS IN NEUROSCIENCES (2000)
A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa
O Rascol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Evaluation of a measurement strategy for Parkinson's disease: Assessing patient health-related quality of life
AM Damiano et al.
QUALITY OF LIFE RESEARCH (2000)
Share Paper
